{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:06:53Z","timestamp":1785539213905,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacadv.2026.102915","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:07Z","timestamp":1784748607000},"page":"102915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-3785","authenticated-orcid":false,"given":"Samer","family":"Al Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Palazzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-4562","authenticated-orcid":false,"given":"Anthony P.","family":"Carnicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacadv.2026.102915_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102915_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102915_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102915_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102915_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9921","key":"10.1016\/j.jacadv.2026.102915_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102915_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102915_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment","volume":"83","author":"Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102915_bib9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102915_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with Atrial Fibrillation in Community Practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"JAHA"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102915_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s11239-021-02416-4","article-title":"Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting","volume":"52","author":"Afzal","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102915_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US medicare beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"13","key":"10.1016\/j.jacadv.2026.102915_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.124.069857","article-title":"Heterogeneity of treatment effects in clinical trials: overview of multivariable approaches and practical recommendations","volume":"150","author":"Bellavia","year":"2024","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102915_bib14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/jama.2021.20552","article-title":"Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals","volume":"326","author":"Angus","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102915_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ahj.2020.12.002","volume":"233","author":"Carnicelli","year":"2021","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102915_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102915_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102915_bib18","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102915_bib19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102915_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag246","article-title":"Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF","author":"Chao","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102915_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2022.842306","article-title":"Phenotype clustering in health care: a narrative review for clinicians","volume":"5","author":"Loftus","year":"2022","journal-title":"Front Artif Intell"},{"key":"10.1016\/j.jacadv.2026.102915_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107778","article-title":"Unsupervised clustering approach to assess heterogeneity of treatment effects across patient phenotypes in randomized clinical trials","volume":"148","author":"Bellavia","year":"2025","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacadv.2026.102915_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/11795468221133611","article-title":"XGBoost, A novel explainable AI technique, in the prediction of myocardial infarction: a UK biobank cohort study","volume":"16","author":"Moore","year":"2022","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.jacadv.2026.102915_bib24","series-title":"Hands-On Machine Learning with R","author":"Boehmke","year":"2019"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102915_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jacadv.2026.102915_bib26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102915_bib27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.123.066279","article-title":"Efficacy and safety of Non\u2013Vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: an individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102915_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","author":"Kent","year":"2018","journal-title":"BMJ"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:23:34Z","timestamp":1785529414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26003364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772963X26003364"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102915","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102913","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102915"}}